AstraZeneca, Britain's largest pharmaceutical company, is reportedly in discussions to take over its US rival Bristol Myers Squibb (BMS) in a deal that would create a pharmaceutical group valued at nearly $400bn (£300bn). The potential acquisition, first reported by the Financial Times, would mark one of the largest pharmaceutical mergers in history and would position the combined entity as the world's fourth-largest drugmaker by market value.
Details of the Proposed Merger
AstraZeneca, led by long-time chief executive Pascal Soriot, is the second-biggest listed company in the UK, with a market value of approximately £196bn prior to the news. BMS, headquartered in Princeton, New Jersey, is known for its cancer treatments and holds a market value of $133bn. A tie-up between the two would create a formidable force in the global pharmaceutical industry, combining AstraZeneca's strengths in oncology, respiratory, and cardiovascular drugs with BMS's portfolio of cancer immunotherapies and other specialties.
The talks are said to be at an early stage, and there is no guarantee that a deal will be reached. However, the potential merger has already captured the attention of investors and industry analysts, given the scale and strategic implications. If completed, it would be the biggest pharmaceutical deal since the $63bn merger of Pfizer and Warner-Lambert in 2000, and would dwarf recent mega-mergers such as the $39bn acquisition of Seagen by Pfizer in 2023.
Market Reaction and Context
The news of the potential merger comes amid a volatile period for global markets. On Monday, crude oil prices fell sharply, while stocks and government bonds rallied after former President Donald Trump cancelled planned strikes on Iran and claimed that peace talks were about to resume. Brent crude was trading 5% lower at $83.47 a barrel by lunchtime, after falling as much as 7.3% to $81.55 a barrel. US West Texas Intermediate dropped more than 5% to $79.47 a barrel.
Both global oil benchmarks had jumped more than 20% in July following escalating fighting between the US and Iran, and attacks on several tankers in the Strait of Hormuz had revived fears for the safety of vessels transiting that critical shipping passage. The cancellation of the strikes and the prospect of renewed peace talks helped ease those concerns, leading to a sell-off in oil and a rally in equities and bonds.
UK Manufacturing Growth
In other economic news, UK manufacturers ramped up production last month for the fourth consecutive month, at the fastest pace in almost two years, according to a leading survey of the industry. The S&P Global poll of manufacturers found them in an upbeat mood in July, though anxious about the prospect of a long war in the Middle East that could block supplies of oil and gas and raise production costs.
Uncertainty about the outcome of the war meant the S&P Global purchasing managers' index (PMI) dipped in July, but it maintained a run of nine months of expansion. The PMI, which tracks activity in the sector, fell back to 51.9 in July, down from 52.5 in June, despite the rise in manufacturing output growth. A reading above 50 denotes a period of expansion.
Yen Strengthens After Joint Intervention
Meanwhile, the yen hit its highest level in three months after Japan and the US launched a combined operation to support the Japanese currency. The yen strengthened to ¥155 to the US dollar on Monday, its highest level since early May, after Tokyo and Washington confirmed they had carried out a rare joint currency intervention late last week.
Tokyo's finance ministry said on Monday that the two governments had conducted coordinated yen-buying intervention and would not hesitate to take further action. The intervention came after the yen had weakened to a 40-year low of almost ¥164 to the dollar last week. Donald Trump told reporters on Sunday: "They have a weakening yen, and they wanted a little bit of help. And we're always there for Japan."
